Comparison
Retatrutide vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
2381089-83-2
57773-63-4
Molecular weight
4731.6 g/mol
1311.45 g/mol
Half-life
144 h
3 h
Sequence
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSpGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
4
4
Effects recorded
4
3
Open conflicts
0
0
Documented adverse events
2
3